avidinorubicin manufacturers
- Avidinorubicin
-
- $2500.00
-
2026-04-21
- CAS:135447-13-1
- Purity:
- Supply Ability: 10g
|
| | avidinorubicin Basic information |
| Product Name: | avidinorubicin | | Synonyms: | avidinorubicin;2,6-Epoxy-2H-naphthaceno[1,2-b]oxocin-9,16-dione, 5-[[O-4-O-(3-carboxy-1-oxopropyl)-2,6-dideoxy-3-O-methyl-α-L-lyxo-hexopyranosyl-(1→4)-O-3-amino-2,3,6-trideoxy-3-C-methyl-β-L-ribo-hexopyranosyl-(1→4)-3-amino-2,3,6-trideoxy-3-C-methyl-β-L-ribo-hexopyranosyl]oxy]-4-(dimethylamino)-3,4,5,6,11,12,13,14... | | CAS: | 135447-13-1 | | MF: | C60H86N4O22 | | MW: | 1215.35 | | EINECS: | | | Product Categories: | | | Mol File: | 135447-13-1.mol |  |
| | avidinorubicin Chemical Properties |
| density | 1.44±0.1 g/cm3(Predicted) | | pka | 4.37±0.17(Predicted) |
| | avidinorubicin Usage And Synthesis |
| Description | Avidinorubicin is a novel anthracycline with platelet aggregation inhibitory activity. | | Uses | Avidinorubicin is an antimicrobial agent found in Streptomyces avidinii, exhibiting activity against both Gram-positive and Gram-negative bacteria. Additionally, Avidinorubicin inhibits thrombin (HY-114164)-induced platelet aggregation, with an IC50 of 7.9 μM[1]. | | References | [1] Aoki M, et al. Structural studies on avidinorubicin, a novel anthracycline with platelet aggregation inhibitory activity. J Antibiot (Tokyo). 1991 Jun;44(6):635-45. DOI:10.7164/antibiotics.44.635
[2] Yang J, et al. Recent advances in chemical synthesis of amino sugars[J]. Molecules, 2023, 28(12): 4724. |
| | avidinorubicin Preparation Products And Raw materials |
|